Decline slowed since 2011; was higher among large and medium\/small metros versus rural counties<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Dec. 23, 2021 (HealthDay News) — During 1999 to 2019, there was a decline in premature mortality attributable to acute myocardial infarction (AMI), according to a study published online Dec. 22 in the Journal of the American Heart Association<\/em>.<\/p>\n Sourbha S. Dani, M.D., from Beth Israel Lahey Health in Burlington, Massachusetts, and colleagues examined premature (younger than 65 years of age) age-adjusted AMI mortality rates per 100,000 using the U.S. Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research death certificate database and assessed the average annual percentage change from 1999 to 2019.<\/p>\n The researchers found that the age-adjusted AMI mortality rate was 13.4 per 100,000 overall. Compared with young adults, women, non-Hispanic White adults, and urban counties, higher mortality was seen among middle-aged adults, men, non-Hispanic Black adults, and rural counties, respectively. The age-adjusted AMI mortality rate decreased at an average annual percentage change of \u00e2\u0088\u00923.4 percent per year between 1999 and 2019; the average annual percentage change showed a higher decline among large and medium\/small metros versus rural counties (\u00e2\u0088\u00924.2 and \u00e2\u0088\u00923.3 per year, respectively, versus \u00e2\u0088\u00922.4 per year). After an initial decline between 1999 and 2011 (\u00e2\u0088\u00924.3 per year), there was a deceleration in the average annual percentage change in mortality since 2011 (\u00e2\u0088\u00922.1 per year). Across both sexes, all ethnicities and races, and urban\/rural counties, these trends were consistent.<\/p>\n “These findings have sizeable public health implications regarding identifying clinical differences and social vulnerabilities in critical demographic subgroups and geographic hotspots,” the authors write.<\/p>\n Two authors disclosed financial ties to the pharmaceutical industry.<\/p>\n